Department of Radiation Oncology, Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Fujian, 361003, PR China.
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong, 510060, PR China.
Biomark Med. 2019 Aug;13(12):1005-1012. doi: 10.2217/bmm-2019-0209. Epub 2019 Jun 25.
To assess the association between established clinicopathological variables and the 21-gene recurrence score (RS) stratification of invasive lobular carcinoma (ILC) of the breast. We identified 9030 ILC patients from the Surveillance, Epidemiology and End Results database. Older age, higher grade tumor and progesterone receptor (PR)-negative disease were independent predictors of high-risk RS stratification. Among patients with PR-positive tumors, 3, 6 and 15% with well-differentiated (G1), moderately-differentiated (G2) and poorly and/or undifferentiated (G3) disease were in the high-risk cohort, respectively. In patients with PR-negative tumors: 16, 24 and 41% of patients with G1, G2 and G3 disease were in the high-risk cohort, respectively. The 21-gene RS testing may not be necessary for patients with PR+/G1-2 ILC.
评估已建立的临床病理变量与乳腺浸润性小叶癌（ILC）21 基因复发评分（RS）分层之间的关系。我们从监测、流行病学和最终结果数据库中确定了 9030 例 ILC 患者。年龄较大、肿瘤分级较高和孕激素受体（PR）阴性疾病是高风险 RS 分层的独立预测因素。在 PR 阳性肿瘤患者中，分别有 3%、6%和 15%的高分化（G1）、中分化（G2）和低分化/未分化（G3）肿瘤患者处于高危队列。在 PR 阴性肿瘤患者中：G1、G2 和 G3 疾病的患者分别有 16%、24%和 41%处于高危队列。对于 PR+/G1-2 ILC 患者，21 基因 RS 检测可能不是必需的。
